JP2020510028A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510028A5
JP2020510028A5 JP2019548709A JP2019548709A JP2020510028A5 JP 2020510028 A5 JP2020510028 A5 JP 2020510028A5 JP 2019548709 A JP2019548709 A JP 2019548709A JP 2019548709 A JP2019548709 A JP 2019548709A JP 2020510028 A5 JP2020510028 A5 JP 2020510028A5
Authority
JP
Japan
Prior art keywords
nausea
delivery device
drug delivery
inducing
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019548709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021594 external-priority patent/WO2018165462A1/en
Publication of JP2020510028A publication Critical patent/JP2020510028A/ja
Publication of JP2020510028A5 publication Critical patent/JP2020510028A5/ja
Priority to JP2023007454A priority Critical patent/JP2023061945A/ja
Pending legal-status Critical Current

Links

JP2019548709A 2017-03-08 2018-03-08 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法 Pending JP2020510028A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023007454A JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468399P 2017-03-08 2017-03-08
US62/468,399 2017-03-08
PCT/US2018/021594 WO2018165462A1 (en) 2017-03-08 2018-03-08 Apparatus and methods for administration of a nauseogenic compound from a drug delivery device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007454A Division JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Publications (2)

Publication Number Publication Date
JP2020510028A JP2020510028A (ja) 2020-04-02
JP2020510028A5 true JP2020510028A5 (enExample) 2021-04-22

Family

ID=61692164

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548709A Pending JP2020510028A (ja) 2017-03-08 2018-03-08 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
JP2023007454A Pending JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023007454A Pending JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Country Status (10)

Country Link
US (1) US20200188479A1 (enExample)
EP (1) EP3592376A1 (enExample)
JP (2) JP2020510028A (enExample)
KR (1) KR20190126335A (enExample)
CN (1) CN110545838A (enExample)
AU (1) AU2018231249A1 (enExample)
CA (1) CA3055759A1 (enExample)
IL (1) IL269001A (enExample)
MX (1) MX2019010651A (enExample)
WO (1) WO2018165462A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
US20230158116A1 (en) * 2020-04-20 2023-05-25 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
US20250268231A1 (en) * 2024-02-27 2025-08-28 Ashop Commerce Pty Ltd. System and method for monitoring and controlling pet activity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306551A (pt) * 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
EP1041968B1 (en) 1997-12-29 2004-03-03 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ATE342051T1 (de) 1997-12-30 2006-11-15 Alza Corp Verabreichungssystem für wirkstoffe mit einem membranstöpsel
EP1060191B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
DE69906132T2 (de) 1998-12-31 2003-12-18 Alza Corp., Mountain View Osmotisches verabreichungsystem mit raumsparenden kolben
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
AU2006208131A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
EP2007804B1 (en) * 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en) * 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120329711A1 (en) * 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013083826A2 (en) * 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
PL2838914T3 (pl) 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
EP2992008B1 (en) 2013-05-02 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Therapeutic peptides
US10479868B2 (en) * 2014-09-04 2019-11-19 Nano Precision Medical, Inc. Polymeric stabilizing formulations
WO2017200944A1 (en) * 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
KR20240037175A (ko) * 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
AU2018206539A1 (en) * 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Similar Documents

Publication Publication Date Title
AU2002318211B2 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
AU2002318211A1 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
CN112512633A (zh) 使用gip/glp1共激动剂用于治疗的方法
IL312012A (en) Compositions and methods for the treatment of opioid overdose
JP2019515899A5 (enExample)
RU2015101826A (ru) Применение долгодействующих пептидов glp-1
RU2013133803A (ru) Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
CN104271149A (zh) 经皮递送装置
RU2011105029A (ru) Доставка октреотида из сухих лекарственных форм
KR20130113443A (ko) 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
JP2016539921A5 (enExample)
JP2014514289A (ja) ２型糖尿病患者における低血糖症の予防
EP4198059A1 (en) Modulation of cellular stress
US20180092965A1 (en) Treatment Type 2 Diabetes Mellitus Patients
JP2020510628A5 (enExample)
CN110769812A (zh) 用于施用胰高血糖素样肽类似物的微针系统
JP2020500864A5 (enExample)
Shaw et al. Metabolic intervention in surgical patients. An assessment of the effect of somatostatin, ranitidine, naloxone, diclophenac, dipyridamole, or salbutamol infusion on energy and protein kinetics in surgical patients using stable and radioisotopes
KR20250029908A (ko) 티르제파티드 조성물 및 용도
Cohen Reinforcement and Rapid Delivery Systems: Understanding Adverse
WO2011112167A1 (en) Compositions and methods for diabetes treatment
Kaur et al. Translational aspects of glucagon: Current use and future prospects
JP2023510609A (ja) Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Robinson et al. Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec